-- Kintor Pharmaceutical (HKG:9939) said its sales since the start of 2026 have exceeded its full-year 2025 total, driven by strong growth in its B2C and B2B businesses, according to a Monday Hong Kong bourse filing.
Shares of the pharmaceutical firm were up nearly 2% in Tuesday morning trade.
The company said year-to-date revenue reached about 34 million yuan, surpassing the 32.7 million yuan sales recorded for all of last year.
Kintor said it plans to use cash flow from these businesses to support the development and commercialization of its core drug pipeline.